Dambkowski Carl 4

What Happened

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (APGE), exercised options to acquire 4,125 shares at $22.86 per share (cost $94,298) and sold 5,500 shares in an open market transaction at $78.71 per share (gross proceeds $432,905) on June 3, 2026. The Form 4 also shows a related derivative entry for 4,125 shares at $0.00 reflecting the conversion/cancellation of the derivative instrument in connection with the exercise.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely filing).
• Exercise (code M): 4,125 shares acquired at $22.86 each — total $94,298.
• Sale (code S): 5,500 shares sold at $78.71 each — total $432,905.
• Derivative entry: 4,125 shares "Disposed" at $0.00 tied to the exercise mechanics.
• Footnote F1: The sale was executed under a Rule 10b5-1 trading plan adopted Sept 22, 2025.
• Footnote F2: The option exercised is part of a larger option grant representing the right to purchase 175,345 shares, which vests in 48 equal monthly installments through Dec 18, 2027, subject to continued service.
• Shares owned after the transactions are not specified in the provided filing details.

Context

Exercising options to acquire shares is a common way for insiders to convert vested derivatives into stock; the filing shows the shares were then partially sold in the open market. The sale was conducted under a pre-established 10b5-1 plan, which typically schedules trades in advance to avoid questions about trading on material nonpublic information.